Bovine vaccinia (BV) is an infectious disease caused by Vaccinia virus (VACV) characterized by vesicular and exanthematic lesions, mainly in cattle. Although BV has been described in some Brazilian regions in the last decades, official information regarding the current prevalence in bovine herds of Midwestern Brazil is lacking. Thus, the current study aimed to estimate the seroprevalence and risk factors associated with BV in cattle in the Distrito Federal (DF), Brazil. Sera of 312 cows of 64 herds were tested by virus-neutralizing test for VACV antibodies. Herd and animal seroprevalence were estimated to be 33.3% (CI 95%: 18.2-48.3%) and 10.6% (CI 95%: 1.0-20.2%), respectively. Seropositive cows were detected in dairy, beef, and mixed-purpose farms. The results of an epidemiological questionnaire showed that no risk factor analyzed was positively associated with seropositivity to VACV. There was no significant association between type of milking (manual/mechanic) and seropositivity to VACV; however, most seropositive cows were present in farms with high daily milk production and high number of lactating and adult cows. Our results indicate that VACV circulates in many regions of DF with considerable prevalence in dairy cows. Control measures to restrict VACV circulation and consequences of the infection may be advisable.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882533PMC
http://dx.doi.org/10.1007/s42770-021-00641-wDOI Listing

Publication Analysis

Top Keywords

bovine vaccinia
8
distrito federal
8
federal brazil
8
seropositive cows
8
seropositivity vacv
8
cows
6
vacv
6
seroprevalence bovine
4
vaccinia cows
4
cows correlation
4

Similar Publications

Vaccine candidates based on MVA viral vectors expressing VP2 or VP7 confer full protection against Epizootic hemorrhagic disease virus in IFNAR(-/-) mice.

J Virol

December 2024

Centro de Investigación en Sanidad Animal (CISA), Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Valdeolmos, Madrid, Spain.

Article Synopsis
  • Epizootic hemorrhagic disease (EHD) is a serious condition affecting livestock, caused by the emerging EHD virus, with recent outbreaks in Europe highlighting the urgent need for vaccine development.
  • Researchers have developed two MVA-vectored vaccine candidates—one targeting protein VP2 of EHDV-8 and another targeting VP7 of EHDV-2—that show promise in protecting mice from EHD.
  • The VP7 vaccine candidate is particularly noteworthy as it successfully protects against multiple EHDV strains without requiring neutralizing antibodies, marking it as a potential multiserotype vaccine solution in the fight against EHD.
View Article and Find Full Text PDF

A global outbreak of monkeypox (mpox) caused by the mpox virus (MPXV) has posed a serious threat to public health worldwide, thus calling for the urgent development of antivirals and vaccines to curb its further spread. In this study, we screened 41 anhydride-modified proteins and found that 3-hydroxyphthalic anhydride-modified β-lactoglobulin (3HP-β-LG), a clinically used anti-HPV agent, was highly effective in inhibiting infection of vaccinia virus Tiantan strain (VACV-VTT) and MPXV. Mechanistic studies demonstrated that 3HP-β-LG bound to the virus, not the host cell, by targeting the early stage of virus entry, possibly through the interaction between the amino acids with negatively charges in 3HP-β-LG and the key amino acids with positive charges in the target region of A29L, a key surface protein of MPXV.

View Article and Find Full Text PDF
Article Synopsis
  • A new compound called TLD-1433 (Ruvidar™) has strong properties against bacteria, cancer, and some viruses.
  • When it was tested, TLD-1433 was found to effectively kill 50% of the H1N1 flu virus without needing special light, and even more when it was activated by light.
  • It also worked against other viruses like human coronavirus and Zika, but it needed higher amounts for non-enveloped viruses like adenovirus, and its effectiveness changed depending on temperature and other conditions.
View Article and Find Full Text PDF

Vaccination is the best strategy to control Paratuberculosis (PTB), which is a significant disease in cattle and sheep. Previously we showed the humoral and cellular immune response induced by a novel vaccine candidate against PTB based on the Argentinian Mycobacterium avium subspecies paratuberculosis (Map) 6611 strain. To improve 6611 immunogenicity and efficacy, we evaluated this vaccine candidate in mice with two different adjuvants and a heterologous boost with a recombinant modified vaccinia Ankara virus (MVA) expressing the antigen 85A (MVA85A).

View Article and Find Full Text PDF

In this study, we demonstrated the antiviral efficacy of hesperetin against multiple poxviruses, including buffalopox virus (BPXV), vaccinia virus (VACV), and lumpy skin disease virus (LSDV). The time-of-addition and virus step-specific assays indicated that hesperetin reduces the levels of viral DNA, mRNA, and proteins in the target cells. Further, by immunoprecipitation (IP) of the viral RNA from BPXV-infected Vero cells and a cell-free RNA-IP assay, we demonstrated that hesperetin-induced reduction in BPXV protein synthesis is also consistent with diminished interaction between eukaryotic translation initiation factor eIF4E and the 5' cap of viral mRNA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!